Eli Lilly Posts a Huge Earnings Miss. Should Investors Be Worried?
Healthcare giant Eli Lilly (NYSE: LLY) has been trading at an inflated valuation for some time thanks to excitement around ...
Eli Lilly's Zepbound and Mounjaro are no longer in shortage. Here's where their sales still disappointed
Eli Lilly's blockbuster weight loss drug Zepbound and diabetes treatment Mounjaro posted weaker-than-expected sales for the ...
Americans seeking Eli Lilly and Novo Nordisk’s weight-loss drugs turn to compounded market
An injection pen of Zepbound, Eli Lilly’s weight-loss drug ... which may have dampened demand temporarily, the company said.
BioSpace5d
Eli Lilly’s Q3 Miss for Mounjaro, Zepbound Highlights Dependency on Wholesalers
Lilly CEO Dave Ricks in Wednesday’s third-quarter earnings call acknowledged that the company is at the mercy of wholesaler ...
Eli Lilly plans to begin advertising weight-loss drug Zepbound
Eli Lilly ( LLY) is planning to advertise its blockbuster weight loss drug, Zepbound, for the first time next month. Despite ...
Eli Lilly's Zepbound sales, Pfizer wants in on weight loss drugs, AbbVie's big deal: Pharma news round up
Eli Lilly CEO David Ricks told investors this week that the sale of cheaper, knockoff versions of the company’s blockbuster ...
Eli Lilly stock tumbles after drug giant misses estimates and slashes profit guidance
Skyrocketing demand for weight loss and diabetes drugs has forced Eli Lilly and Novo Nordisk, to invest billions to increase ...
NBC Washington7d
Eli Lilly's Zepbound and Mounjaro are no longer in shortage. Here's where their sales still disappointed
Ricks said Eli Lilly had yet to begin what the company calls "demand-stimulating activities," or advertising and promoting, for Zepbound. The drugmaker will start those efforts in November ...